(Q38992309)

8 September 2017

1 reference

title

HIV-associated opportunistic CNS infections: pathophysiology, diagnosis and treatment (English)

1 reference

8 September 2017

4

Martha Quezado

1 reference

8 September 2017

Lauren N Bowen

1

1 reference

8 September 2017

Bryan Smith

series ordinal

2

1 reference

8 September 2017

Daniel Reich

series ordinal

3

1 reference

8 September 2017

Avindra Nath

series ordinal

5

1 reference

8 September 2017

language of work or name

English

0 references

publication date

1 October 2016

1 reference

8 September 2017

published in

Nature Reviews Neurology

1 reference

8 September 2017

volume

12

1 reference

8 September 2017

issue

11

1 reference

8 September 2017

page(s)

662-674

1 reference

Development of a multiplex real-time PCR for the simultaneous detection of herpes simplex and varicella zoster viruses in cerebrospinal fluid and lesion swab specimens

8 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Survival after neuroAIDS: Association with antiretroviral CNS Penetration-Effectiveness score

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

The host-parasite relationship of Toxoplasma gondii in the brains of chronically infected mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Toxoplasma gondii: determination of the onset of chronic infection in mice and the in vitro reactivation of brain cysts.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Activated microglia contribute to neuronal apoptosis in Toxoplasmic encephalitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Outbreak of central-nervous-system toxoplasmosis in western Europe and North America

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Trends in AIDS-defining opportunistic illnesses incidence over 25 years in Rio de Janeiro, Brazil

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Clinical features, outcome and survival from cerebral toxoplasmosis in Edinburgh AIDS patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Toxoplasma gondii seroprevalence in the United States 2009-2010 and comparison with the past two decades

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Prevalence, Associated Factors, and Prognostic Determinants of AIDS‐Related Toxoplasmic Encephalitis in the Era of Advanced Highly Active Antiretroviral Therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

A Novel Case of Solitary Cerebral Toxoplasmosis Mimicking Glioblastoma as the First Presentation of HIV.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Movement disorders with cerebral toxoplasmosis and AIDS.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Diffuse "encephalitic" cerebral toxoplasmosis in AIDS. Report of four cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Clinical patterns of uveitis in two ophthalmology centres in Bogota, Colombia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Referral patterns of uveitis in a tertiary eye care center.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Toxoplasma chorioretinitis diagnosed by histopathology in a patient with AIDS.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Ocular toxoplasmosis in human immunodeficiency virus-infected patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Roth Spots in Ocular Toxoplasmosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

A 10-year retrospective comparison of two target sequences, REP-529 and B1, for Toxoplasma gondii detection by quantitative PCR.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Diagnosis of cerebral toxoplasmosis in AIDS patients in Brazil: importance of molecular and immunological methods using peripheral blood samples

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

IgG4 specific to Toxoplasma gondii excretory/secretory antigens in serum and/or cerebrospinal fluid support the cerebral toxoplasmosis diagnosis in HIV-infected patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Diagnostic accuracy of HIV-associated central nervous system toxoplasmosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Clinically Available Medicines Demonstrating Anti-Toxoplasma Activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Development of an Orally Available and Central Nervous System (CNS) Penetrant Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitor with Minimal Human Ether-a-go-go-Related Gene (hERG) Activity for the Treatment of Toxoplasmosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Anti-JC virus antibodies: implications for PML risk stratification

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

The natural history of progressive multifocal leukoencephalopathy in patients with AIDS. Canadian PML Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Progressive multifocal leukoencephalopathy: a confused woman, an ambitious virus and an unusual MRI.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Progressive multifocal leukoencephalopathy in a patient with acquired immunodeficiency syndrome (AIDS) manifesting Gerstmann's syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Progressive multifocal leukoencephalopathy masquerading as cerebellar infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Progressive multifocal leukoencephalopathy presenting with an isolated focal movement disorder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Isolated cortical blindness without simultaneous neurological involvement in progressive multifocal leukoencephalopathy in a patient with human immune deficiency virus infection.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

JC virus granule cell neuronopathy: A novel clinical syndrome distinct from progressive multifocal leukoencephalopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Continued declining incidence and improved survival of progressive multifocal leukoencephalopathy in HIV/AIDS patients in the current era.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Progressive multifocal leukoencephalopathy: value of diffusion-weighted and contrast-enhanced magnetic resonance imaging for diagnosis and treatment control

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Treatment of non-AIDS progressive multifocal leukoencephalopathy with cytosine arabinoside

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

HIV and Tuberculosis: a Deadly Human Syndemic

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Pretreatment intracerebral and peripheral blood immune responses in Vietnamese adults with tuberculous meningitis: diagnostic value and relationship to disease severity and outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

HIV-associated tuberculous meningitis--diagnostic and therapeutic challenges.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Tuberculous meningitis: a uniform case definition for use in clinical research

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Comparison of conventional bacteriology with nucleic acid amplification (amplified mycobacterium direct test) for diagnosis of tuberculous meningitis before and after inception of antituberculosis chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Technology for automated, rapid, and quantitative PCR or reverse transcription-PCR clinical testing.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Rapid molecular detection of tuberculosis and rifampin resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Role of interferon gamma release assay in active TB diagnosis among HIV infected individuals

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Paradoxical reaction in tuberculous meningitis: presentation, predictors and impact on prognosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)--associated tuberculous meningitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Multidrug-resistant tuberculous meningitis in KwaZulu-Natal, South Africa.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Development of cytomegalovirus (CMV) disease may be predicted in HIV-infected patients by CMV polymerase chain reaction and the antigenemia test

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: an open-label dose-ranging study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Opportunistic Neurologic Infections in Patients with Acquired Immunodeficiency Syndrome (AIDS).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Determinants of mortality in a combined cohort of 501 patients with HIV-associated Cryptococcal meningitis: implications for improving outcomes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Pulmonary infection with an interferon-gamma-producing Cryptococcus neoformans strain results in classical macrophage activation and protection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Human Immune Response Varies by the Degree of Relative Cryptococcal Antigen Shedding

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

HIV-associated opportunistic infections of the CNS.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Cryptoccocal meningitis in Yaoundé (Cameroon) HIV infected patients: Diagnosis, frequency and Cryptococcus neoformans isolates susceptibility study to fluconazole

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Multisite validation of cryptococcal antigen lateral flow assay and quantification by laser thermal contrast

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

CNS cryptococcoma in an HIV-positive patient

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Cryptococcal neuroradiological lesions correlate with severity during cryptococcal meningoencephalitis in HIV-positive patients in the HAART era.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Neurological, visual, and MRI brain scan findings in 87 South African patients with HIV-associated cryptococcal meningoencephalitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Cryptococcal meningoencephalitis relapse after an eight-year delay: an interplay of infection and immune reconstitution

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Spectrum of imaging appearances of intracranial cryptococcal infection in HIV/AIDS patients in the anti-retroviral therapy era.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Shunting in cryptococcal meningitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Epidemiological characterization and prognostic factors in patients with confirmed cerebral cryptococcosis in central Taiwan

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

The effect of therapeutic lumbar punctures on acute mortality from cryptococcal meningitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Combination antifungal therapy for cryptococcal meningitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Voriconazole: a novel treatment option for cryptococcal meningitis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

The Investigational Drug VT-1129 Is a Highly Potent Inhibitor of Cryptococcus Species CYP51 but Only Weakly Inhibits the Human Enzyme.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Induction and maintenance therapy of cytomegalovirus central nervous system infection in HIV-infected patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Neurologic cytomegalovirus complications in patients with AIDS: retrospective review of 13 cases and review of the literature

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Clinical characteristics and outcomes of cytomegalovirus retinitis in persons without human immunodeficiency virus infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 1. Retinitis progression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Comparison of treatment regimens for cytomegalovirus retinitis in patients with AIDS in the era of highly active antiretroviral therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Intravitreal triamcinolone acetonide for the treatment of immune recovery uveitis macular edema

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Tuberculous meningitis: presentation, diagnosis and outcome in hiv-infected patients at the douala general hospital, cameroon: a cross sectional study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Spectrums of opportunistic infections and malignancies in HIV-infected patients in tertiary care hospital, China

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.149

Ocular toxoplasmosis in AIDS patients

31 March 2020

1 reference

12 December 2020

Movement disorders in 28 HIV-infected patients

1 reference

12 December 2020

[Aspecific chorioretinitis as initial manifestation of HIV infection and diffuse Toxoplasma encephalitis]

1 reference

12 December 2020

Clinical spectrum in 107 cases of toxoplasmic lymphadenopathy

1 reference

12 December 2020

Current issues in the diagnosis and management of tuberculosis and HIV coinfection in the United States

1 reference

12 December 2020

Natural History and Factors Associated with Early and Delayed Mortality in HIV-Infected Patients Treated of Tuberculosis under Directly Observed Treatment Short-Course Strategy: A Prospective Cohort Study in India

1 reference

12 December 2020

Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of Amer

1 reference

12 December 2020

Early biopsy versus empiric treatment with delayed biopsy of non-responders in suspected HIV-associated cerebral toxoplasmosis: a decision analysis

1 reference

12 December 2020

Multidrug-resistant tuberculous meningitis in patients with AIDS

1 reference

12 December 2020

Prospective Analysis of 55 Cases of Tuberculosis Meningitis (TBM) in North India

1 reference

12 December 2020

10.1038/NRNEUROL.2016.149

Identifiers

DOI

1 reference

Dimensions Publication ID

8 September 2017

1048125449

0 references

1 reference